<DOC>
	<DOCNO>NCT02657447</DOCNO>
	<brief_summary>This study phase I , open label , randomize study ass pharmacokinetics , biodistribution radiation dosimetry 177Lu-DOTA-HH1 ( Betalutin® ) radioimmunotherapy patient relapse non-Hodgkin lymphoma . The study also investigate safety , toxicity efficacy Betalutin pre-dosing .</brief_summary>
	<brief_title>Dosimetry Study Betalutin Treatment Relapsed Non-Hodgkin Lymphoma ( LYMRIT-37-02 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Histologically confirm ( WHO classification ) relapse indolent nonHodgkin Bcell lymphoma follow subtypes : Follicular lymphoma ( follicular grade IIIIA ) , Marginal zone lymphoma ( exclusion MZL large lymphocyte &gt; 50 % ) , Small lymphocytic lymphoma , Lymphoplasmacytoid classical mantle cell lymphoma ( blastoid MCL ) . 2 . Requiring initiation treatment NHL . 3 . Relapsed least one line therapy include rituximab combination chemotherapy regimen . 4 . Exhausted and/or ineligible standard treatment option . 5 . Not candidate autologous allogeneic stem cell transplantation . Patients progression successful stem cell collection highdose therapy autologous stem cell transplantation may consider enrolment . 6 . Age ≥ 18 years.. 7 . A prestudy ECOG performance status 02 . In selected patient ECOG score 3 acceptable clearly lymphomaassociated discretion investigator . 8 . Life expectancy ≥ 3 month . 9 . &lt; 25 % tumour cell bone marrow biopsy prior HH1/Betalutin treatment . At screen patient high level may include , provide patient agree new bone marrow biopsy prior HH1/Betalutin treatment . If amount tumour cell still 25 % rituximab pretreatment , patient need exclude study prior HH1 infusion Betalutin administration . 10 . All patient must least one bidimensionally measurable lesion ( &gt; 1.5 cm large dimension CT scan ) . Patients without target lesion accept individual basis histological organ involvement evaluate response e.g . involvement skin gastrointestinal tract . 11 . Women childbearing potential must : negative serum pregnancy test screen Betalutin injection understand study medication expect teratogenic risk agree use , able comply , highly effective method birth control PearlIndex ≤ 1 % . Contraception require without interruption , 4 week start study drug , throughout study drug therapy 12 month end study drug therapy , even amenorrhoea . 12 . Male subject must agree use condom intercourse throughout study drug therapy follow 12 month . 13 . Patients previously treat native rituximab eligible . 14 . The patient willing able comply protocol , agree return hospital followup visit examination . 15 . The patient fully inform study sign informed consent form . 16 . Negative HAMA test . 1 . Medical contraindication , include uncontrolled infection , severe cardiac , pulmonary , neurologic , psychiatric metabolic disease , steroid require asthma/allergy , know HIV positive . 2 . Laboratory value screen : Absolute Neutrophil Counts ( ANC ) ≤ 1.5 x 109 /l Platelet count ≤ 150 x 109 /l ( platelet count D28 must 20 % low result screen ) Total bilirubin ≥ 30 mmol/l ALP ALAT ≥ 4x normal level e. GFR &lt; 60 ml/min/1.73 m2 measure CKDEPI method . 3 . Known suspected CNS involvement lymphoma 4 . Previous total body irradiation , irradiation &gt; 25 % patient 's bone marrow . 5 . Chemotherapy , immunotherapy another investigational drug receive within last 4 week prior patient enter screening . 6 . Earlier treatment radioimmunotherapy . 7 . Exposure another CD37 target drug . 8 . Concurrent participation another therapeutic treatment trial . 9 . Previous hematopoietic stem cell transplantation ( autologous allogenic ) . 10 . Pregnant lactating woman . 11 . Transformed potentially transform NHL 12 . Receipt live , attenuated vaccine within 30 day prior enrolment 13 . Test positive hepatitis B ( HBsAg antiHBc ) 14 . A known hypersensitivity rituximab , HH1 , Betalutin murine proteins excipient use rituximab , HH1 Betalutin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Lu-177</keyword>
	<keyword>Phase I study</keyword>
	<keyword>Betalutin</keyword>
	<keyword>ARC</keyword>
	<keyword>Antibody Radionuclide Conjugate</keyword>
	<keyword>HH1</keyword>
	<keyword>Rituximab</keyword>
	<keyword>177Lu-DOTA-HH1</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma Non-Hodgkin</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Marginal Zone Lymphoma</keyword>
	<keyword>Lymphoplasmacytoid</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Histological Type</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Classical Mantle Cell Lymphoma</keyword>
	<keyword>Lilotomab</keyword>
</DOC>